World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
43332
World Ranking
7591
National Ranking
743

Brian Gazzard publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Brian Gazzard sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 629 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Brian Gazzard D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Brian Gazzard sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 102 D-Index — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Brian Gazzard is affiliated with St Bartholomew's Hospital in the United Kingdom. Their research primarily addresses HIV/AIDS with a focus on treatment, prevention, and public health strategies.

The scientist's fields of study include Medicine and Immunology and Microbiology, with subfields covering Infectious Diseases, Virology, Epidemiology, and Sociology and Political Science.

Brian Gazzard's main research topics encompass HIV/AIDS Research and Interventions, HIV/AIDS drug development and treatment, HIV Research and Treatment, as well as issues related to HIV, Drug Use, Sexual Risk, and Sex work and related issues.

Their recent publications are as follows:

  • HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment (2023, The Lancet HIV)
  • 2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings (2021, Journal of Antimicrobial Chemotherapy)
  • Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT) (2024, EClinicalMedicine)

Frequent collaborators in their research include Carlo Torti, Alejandro Arenas-Pinto, Amanda Clarke, Ian Williams, and Margaret Johnson.

Brian Gazzard's work is published in several scientific venues including The Lancet HIV, EClinicalMedicine, and the Journal of Antimicrobial Chemotherapy.

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

    Sheena McCormack;David T. Dunn;Monica Desai;David I. Dolling

  • Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel

    Charles C. J. Carpenter;David A. Cooper;Margaret A. Fischl;Jose M. Gatell

  • Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

    Joel E. Gallant;Edwin Dejesus;José R. Arribas;Anton L. Pozniak

  • Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panel

    Scott M. Hammer;Michael S. Saag;Mauro Schechter;Julio S. G. Montaner

  • Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

    F van Leth;P Phanuphak;K Ruxrungtham;E Baraldi

  • Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

    Graeme J. Moyle;Brian G. Gazzard;David A. Cooper;José Gatell

  • Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

    Patrick G. Yeni;Scott M. Hammer;Martin S. Hirsch;Michael S. Saag

  • Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome.

    John C Walsh;Sundhiya Mandalia;Brian G Gazzard

  • Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

    Mark E. Sharkey;Ian Teo;Thomas Greenough;Natalia Sharova

  • Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection

    Thomas Powles;David Robinson;Justin Stebbing;Jonathan Shamash

  • Increasing burden of liver disease in patients with HIV infection

    Deepak Joshi;John O'Grady;Doug Dieterich;Brian Gazzard

  • Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection.

    Cormac Cosgrove;James E. Ussher;Andri Rauch;Kathleen Gärtner

  • Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.

    Scott M Hammer;Michael S Saag;Mauro Schechter;Julio S G Montaner

  • Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.

    Jose R. Arribas;Anton L. Pozniak;Joel E. Gallant;Edwin DeJesus

  • Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

    Frank van Leth;Prahpan Phanuphak;Erik Stroes;Brian Gazzard

  • Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma

    M. Bower;M. Nelson;A.M. Young;C. Thirlwell

  • Epidemiology and Predictive Factors for Chemokine Receptor Use in HIV-1 Infection

    Graeme J. Moyle;Adrian Wildfire;Sundhiya Mandalia;Howard Mayer

  • Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

    Anton L. Pozniak;Joel E. Gallant;Joel E. Gallant;Edwin DeJesus;Jose R. Arribas;Jose R. Arribas

  • Relation between HIV viral load and infectiousness : a model-based analysis. Commentary

    Geoffrey P. Garnett;Brian Gazzard;David P. Wilson;Matthew G. Law

Frequent Co-Authors

Mark Nelson
Mark Nelson University of Vermont
Mark Bower
Mark Bower Imperial College London
Justin Stebbing
Justin Stebbing Imperial College London
Graeme Moyle
Graeme Moyle Chelsea and Westminster Hospital NHS Foundation Trust
Anton Pozniak
Anton Pozniak London School of Hygiene & Tropical Medicine
Martin Fisher
Martin Fisher University of Sussex
Frances Gotch
Frances Gotch Imperial College London
Mark Nelson
Mark Nelson Imperial College London
Philippa Easterbrook
Philippa Easterbrook King's College London
Caroline Sabin
Caroline Sabin University College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine, it’s important to know there are multiple educational pathways and related degrees that lead to promising healthcare roles. For those interested in practical nursing, entry requirements may vary, and you might wonder: do I need to take the TEAS test for LPN? Exploring programs with flexible prerequisites can open doors for aspiring nurses.

Healthcare is more than direct patient care. If you're intrigued by the business side of medicine, a healthcare administration degree can prepare you for leadership roles in hospitals, clinics, and health organizations—many of which are offered online for busy professionals.

Career advancement is also accessible through bridge programs like RN to NP programs, which allow registered nurses to become nurse practitioners while completing their education online or in hybrid formats.

For those interested in wellness and prevention, earning an online degree in nutrition offers a science-based path into patient care, community health, and health education.

Whether you’re at the start of your journey or looking to specialize, these online degrees and pathways provide flexible options to build a rewarding healthcare career in the USA.

Best Scientists Citing Brian Gazzard

Trending Scientists

Recently Published Articles